We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVRP LONDON, April 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the three months ended March 31, 2020 on Thursday, April 30, 2020 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss the financial results and provide a corporate update. To participate, please dial one of the following numbers and reference conference ID 2667888: -- 866-940-4574 for callers in the United States -- 0800 028 8438 for callers in the United Kingdom -- 0800 181 5287 for callers in Germany A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, https://www.globenewswire.com/Tracker?data=ssqFVlkm7mXk1L1Ba-690fKqST3L0EtJAjEyh61Yfrg4sFZB5kFguneEA0MRTprVtvfumkVtHzZFJ9ZvQEuM7vHN-g6TomXAvTcbkXVzOUM= www.veronapharma.com, and an audio replay will be available there for 30 days. About Verona Pharma Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Verona Pharma is currently evaluating three formulations of ensifentrine for the treatment of COPD in Phase 2 clinical trials: nebulized, dry powder inhaler, and pressurized metered-dose inhaler. Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. Verona Pharma plc Tel: +44 (0)20 3283 4200 ------------------------------------------------------ --------------------------- Victoria Stewart, Director of Communications info@veronapharma.com ------------------------------------------------------ --------------------------- N+1 Singer Tel: +44 (0)20 3283 4200 (Nominated Adviser and UK Broker) ------------------------------------------------------ --------------------------- Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance) ------------------------------------------------------ --------------------------- Tom Salvesen (Corporate Broking) ------------------------------------------------------ --------------------------- Optimum Strategic Communications Tel: +44 (0)20 950 9144 (European Media and Investor Enquiries) verona@optimumcomms.com ------------------------------------------------------ --------------------------- Mary Clark / Eva Haas / Hollie Vile ------------------------------------------------------ --------------------------- Argot Partners Tel: +1 212-600-1902 (US Investor Enquiries) verona@argotpartners.com ------------------------------------------------------ --------------------------- Kimberly Minarovich / Michael Barron ------------------------------------------------------ ---------------------------
(END) Dow Jones Newswires
April 23, 2020 02:00 ET (06:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions